Machine-learning screening identifies two drug-repurposing candidates against tuberculosis
A virtual-screening workflow combined XGBoost and graph-neural-network models to screen 11,576 DrugBank compounds. Researchers selected 15 candidates for evaluation; four met the study’s activity cutoff against Mycobacterium tuberculosis H37Rv. Aldoxorubicin and quarfloxin were further tested against multidrug-resistant isolates, intracellular bacteria and recombinant DNA gyrase. These are laboratory repurposing results, not evidence of patient benefit or clinical safety. A same-team patent-family publication predates the journal article; this record makes no priority claim over patent disclosures. Concentration values are omitted because of inconsistent units in the rendered tables.
Technology: Ensemble virtual screening with XGBoost and graph neural networks
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The article reports follow-up testing of 15 selected compounds, four meeting the authors’ activity cutoff against H37Rv, and additional assays of aldoxorubicin and quarfloxin against multidrug-resistant isolates and recombinant DNA gyrase.
- Still unknown: All reported results are in vitro. The study does not establish patient efficacy, clinical safety or the compounds’ cellular mechanism. Precise concentration values are omitted because table units are inconsistent; an earlier patent-family publication is noted without a priority claim.
- AI role: Multiple learned models, including XGBoost and graph neural networks, predicted antitubercular activity in a DrugBank screen and contributed to selection of candidates for experimental evaluation.
Evidence sources: https://academic.oup.com/bib/article/26/1/bbae696/7934648
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary Oxford Academic full indexed article, including abstract, Methods, results, article history and author affiliations; patent-family chronology checked from the patent family page. A-version patent text was not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.